Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.

Abstract:

BACKGROUND AIMS:Corticosteroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but they are associated with many complications, and less than half of patients have a sustained response. METHODS:To improve outcomes, we performed a retrospective study to analyze the efficacy of the addition of extracorporeal photopheresis (ECP) to low-dose corticosteroids in 37 adult patients (median age, 57 years) with skin-predominant aGVHD (grade I, n = 17; grade II, n = 18; and grade III, n = 2). All patients received ECP in combination with 1 mg/kg prednisone (n = 26) or topical steroids (n = 11). RESULTS:Overall response rate was 81% after a median of three ECP procedures (range, 2-8), including 22 complete responses (CR, 59%) and eight very good partial responses (VGPR, 22%). The 11 patients treated with topical corticosteroids achieved CR. Furthermore, 16 (62%) patients reached prednisone withdrawal at a median of 100 days (range, 42-174 days) after its initiation. Eighteen patients developed chronic GVHD (cGVHD); 11 of them (who were in CR of aGVHD) had a new-onset cGVHD, and seven experienced progressive cGVHD (five non-responding and two VGPR patients). A second-line immunosuppressive treatment was initiated in only five (14%) non-responding patients. With a median follow-up of 31 months (range, 6-57 months) 2-year overall survival and non-relapse mortality were 74% and 11%, respectively. CONCLUSIONS:Overall, the combination of low-dose corticosteroids and ECP appear to be safe and effective for first-line treatment of skin predominant aGVHD.

journal_name

Cytotherapy

journal_title

Cytotherapy

authors

Sestili S,Eder S,Belhocine R,Dulery R,Battipaglia G,Brissot E,Mediavilla C,Banet A,van de Wyngaert Z,Paviglianiti A,Ledraa T,Bonin A,Mohty M,Malard F

doi

10.1016/j.jcyt.2020.03.003

subject

Has Abstract

pub_date

2020-08-01 00:00:00

pages

445-449

issue

8

eissn

1465-3249

issn

1477-2566

pii

S1465-3249(20)30066-9

journal_volume

22

pub_type

杂志文章
  • Bone marrow-derived mesenchymal stromal cells regress aortic aneurysm via the NF-kB, Smad3 and Akt signaling pathways.

    abstract:BACKGROUND AIMS:We have confirmed that aortic aneurysm (AA) can be regressed by the administration of bone marrow-derived mesenchymal stromal cells (BM-MSCs). We investigated the kinetics of signaling pathways in AA following treatment with BM-MSCs. METHODS:Angiotensin II-infused apolipoprotein E-deficient mice were t...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.07.010

    authors: Yamawaki-Ogata A,Oshima H,Usui A,Narita Y

    更新日期:2017-10-01 00:00:00

  • Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.

    abstract:BACKGROUND AIMS:CD1d-restricted invariant natural killer (iNK) T cells are rare regulatory T cells that may contribute to the immune-regulation in allogeneic stem cell transplantation (ASCT). Here, we sought to develop an effective strategy to expand human iNK T cells for use in cell therapy to prevent graft-versus-hos...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2018.05.007

    authors: Trujillo-Ocampo A,Cho HW,Herrmann AC,Ruiz-Vazquez W,Thornton AB,He H,Li D,Qazilbash MA,Ma Q,Porcelli SA,Shpall EJ,Molldrem J,Im JS

    更新日期:2018-08-01 00:00:00

  • Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.

    abstract::Natural killer (NK) cells are members of the innate immune system that recognize target cells via activating and inhibitory signals received through cell receptors. Derived from the lymphoid lineage, NK cells are able to produce cytokines and exert a cytotoxic effect on viral infected and malignant cells. It is their ...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2016.05.018

    authors: Burga RA,Nguyen T,Zulovich J,Madonna S,Ylisastigui L,Fernandes R,Yvon E

    更新日期:2016-11-01 00:00:00

  • Hyperbaric oxygen treatment effects on in vitro cultured umbilical cord blood CD34+ cells.

    abstract:BACKGROUND AIMS:Umbilical cord blood (UCB) provides an alternative source for hematopoietic stem/progenitor cells (HSPCs) in the treatment of hematological malignancies. However, clinical usage is limited due to the low quantity of HSPCs in each unit of cord blood and defects in bone marrow homing. Hyperbaric oxygen (H...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.08.020

    authors: Cheung KY,Berry A,Li D,Aljitawi OS

    更新日期:2018-01-01 00:00:00

  • Transiently redirected T cells for adoptive transfer.

    abstract:BACKGROUND AIMS:T cells can be redirected to reject cancer by retroviral transduction with a chimeric antigen receptor (CAR) or by administration of a bispecific T cell engager (BiTE). We demonstrate that transfection of T cells with messenger (m) RNA coding for CAR is an alternative strategy. METHODS:We describe the ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2010.542461

    authors: Almåsbak H,Rian E,Hoel HJ,Pulè M,Wälchli S,Kvalheim G,Gaudernack G,Rasmussen AM

    更新日期:2011-05-01 00:00:00

  • Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.

    abstract::Targeted adoptive immunotherapy with engineered T cells is a promising treatment for refractory hematologic malignancies. However, many patients achieving early complete remissions ultimately relapse. Immunosuppressive ligands are expressed on tumor and supportive cells in the tumor microenvironment (TME). When activa...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2018.07.005

    authors: Zolov SN,Rietberg SP,Bonifant CL

    更新日期:2018-10-01 00:00:00

  • Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

    abstract:BACKGROUND AIMS:The Quantum® Cell Expansion System (Quantum; Terumo BCT, Inc, Lakewood, CO, USA) is a novel hollow fiber-based device that automates and closes the cell culture process, reducing labor intensive tasks such as manual cell culture feeding and harvesting. The manual cell selection and expansion processes f...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.05.024

    authors: Jones M,Varella-Garcia M,Skokan M,Bryce S,Schowinsky J,Peters R,Vang B,Brecheisen M,Startz T,Frank N,Nankervis B

    更新日期:2013-11-01 00:00:00

  • Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.

    abstract:BACKGROUND AIMS:Tumor antigen-specific cytotoxic T lymphocytes (CTL) have been used in the treatment of human cancer, including leukemia. Several studies have established PR1 peptide, an HLA-A2.1-restricted peptide derived from proteinase 3 (P3), as a human leukemia-associated antigen. PR1-specific CTL elicited in vitr...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2010.506506

    authors: Ma Q,Wang C,Jones D,Quintanilla KE,Li D,Wang Y,Wieder ED,Clise-Dwyer K,Alatrash G,Mj Y,Munsell MF,Lu S,Qazilbash MH,Molldrem JJ

    更新日期:2010-12-01 00:00:00

  • Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy.

    abstract::Mesenchymal stromal cells (MSCs) are multipotent cells derived from various tissues that can differentiate into several cell types. MSCs are able to modulate the response of immune cells of the innate and adaptive immune system. Because of these multimodal properties, the potential use of MSCs for immunotherapies is c...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2017.03.076

    authors: de Wolf C,van de Bovenkamp M,Hoefnagel M

    更新日期:2017-07-01 00:00:00

  • Differential properties of human stromal cells from bone marrow, adipose, liver and cardiac tissues.

    abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSCs), derived from several tissues including bone marrow and adipose tissue, are being evaluated in clinical trials for a range of diseases. Virtually all tissues of the body contain stromal cells, yet it is unknown whether these sources are similar in phenotype and function....

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.07.009

    authors: Kellner J,Sivajothi S,McNiece I

    更新日期:2015-11-01 00:00:00

  • Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences.

    abstract:BACKGROUND:Container integrity is critical for maintaining sterility of cryopreserved cellular therapy products. We investigated a series of catastrophic bag failures, first noticed in early 2001. METHODS:Process records were reviewed for all PBPC and lymphocyte products cryopreserved in bags from January 2000 through...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/146532402761624700

    authors: Khuu HM,Cowley H,David-Ocampo V,Carter CS,Kasten-Sportes C,Wayne AS,Solomon SR,Bishop MR,Childs RM,Read EJ

    更新日期:2002-01-01 00:00:00

  • Establishment, characterization and long-term culture of human endocrine pancreas-derived microvascular endothelial cells.

    abstract:BACKGROUND:In vitro primary cultures of microvascular endothelial cells from endocrine pancreas are difficult to obtain, but can be a very helpful tool for studies of islet biology, transplantation and regenerative medicine. METHODS:We applied a protocol recently described for the isolation and culture of brain microv...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2016.10.005

    authors: Sordi V,Ferri A,Ceserani V,Ciusani E,Dugnani E,Pellegrini S,Nano R,Pecciarini L,Pessina A,Pascucci L,Piemonti L,Alessandri G

    更新日期:2017-01-01 00:00:00

  • Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction.

    abstract:BACKGROUND AIMS:Traditionally, stem cell therapy for myocardial infarction (MI) has been administered as a single treatment in the acute or subacute period after MI. These time intervals coincide with marked differences in the post-infarct myocardial environment, raising the prospect that repeat cell dosing could provi...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.07.016

    authors: Richardson JD,Psaltis PJ,Frost L,Paton S,Carbone A,Bertaso AG,Nelson AJ,Wong DT,Worthley MI,Gronthos S,Zannettino AC,Worthley SG

    更新日期:2014-04-01 00:00:00

  • Fifty-Hertz electromagnetic fields facilitate the induction of rat bone mesenchymal stromal cells to differentiate into functional neurons.

    abstract:BACKGROUND AIMS:Research results have shown that bone mesenchymal stromal cells (BMSC) can different into neural cells. Electromagnetic fields (EMF) play a role in regulating cell proliferation and differentiation, but the mechanisms behind this are unknown. In the present study, we explored the efficacy of EMF on the ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.03.001

    authors: Bai WF,Xu WC,Feng Y,Huang H,Li XP,Deng CY,Zhang MS

    更新日期:2013-08-01 00:00:00

  • Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model.

    abstract:BACKGROUND AIMS:Bone marrow mononuclear cells (BM-MNCs) and bone marrow-derived mesenchymal stem stromal cells (BM-MSCs) could have therapeutic potential for numerous conditions, including ischemia-related injury. Cells transplanted intravascularly may become entrapped in the lungs, which potentially decreases their th...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2014.12.004

    authors: Mäkelä T,Takalo R,Arvola O,Haapanen H,Yannopoulos F,Blanco R,Ahvenjärvi L,Kiviluoma K,Kerkelä E,Nystedt J,Juvonen T,Lehenkari P

    更新日期:2015-04-01 00:00:00

  • Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro.

    abstract:BACKGROUND:Amniotic membrane is a highly promising cell source for tissue engineering. Being part of the placenta, this tissue is abundantly available. It can be processed easily to yield large amounts of epithelial and mesenchymal cells that have shown broad differentiation potential. For tissue-engineering purposes, ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240802345804

    authors: Stadler G,Hennerbichler S,Lindenmair A,Peterbauer A,Hofer K,van Griensven M,Gabriel C,Redl H,Wolbank S

    更新日期:2008-01-01 00:00:00

  • Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation.

    abstract:BACKGROUND AIMS:Adipose tissue is a critical organ that plays a major role in energy balance regulation and the immune response through intricate signals. METHODS:We report on the inter-relation between mature adipocytes and lymphocytes in terms of adipocyte-derived T-cell chemo-attractants and adipocyte metabolic eff...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.06.007

    authors: Poloni A,Maurizi G,Ciarlantini M,Medici M,Mattiucci D,Mancini S,Maurizi A,Falconi M,Olivieri A,Leoni P

    更新日期:2015-09-01 00:00:00

  • CD4(+) CD25(+) regulatory T cells ameliorate Behcet's disease-like symptoms in a mouse model.

    abstract:BACKGROUND AIMS:Behcet's disease (BD) is a chronic, multisystemic inflammatory disorder with arthritic, gastrointestinal, mucocutaneous, ocular, vascular and central nervous system involvement. It is well known that CD4(+) CD25(+) T-regulatory (Treg) cells prevent harmful immune responses to self- and non-self-antigens...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2011.571245

    authors: Shim J,Lee ES,Park S,Bang D,Sohn S

    更新日期:2011-08-01 00:00:00

  • Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma.

    abstract:BACKGROUND AIMS:Dendritic cell (DC)-based therapies could be important strategies for lymphoma treatment. METHODS:AKR/J mice with Dalton's lymphoma were treated with recombinant interleukin-15 (rIL-15)-activated autologous DCs and pulsed with whole tumor cell lysates in the presence or absence of suboptimal doses of t...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.01.006

    authors: Hira SK,Mondal I,Manna PP

    更新日期:2015-05-01 00:00:00

  • Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy.

    abstract:BACKGROUND AIMS:Bone marrow (BM) mesenchymal stromal cells (MSC) represent a novel therapy for severe heart failure with extensive myocardial scarring, especially when performed concurrently with conventional revascularization. However, stem cells are difficult to transport in culture media without risk of contaminatio...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653240903313966

    authors: Chin SP,Poey AC,Wong CY,Chang SK,Teh W,Mohr TJ,Cheong SK

    更新日期:2010-01-01 00:00:00

  • A comparison in therapeutic efficacy of several time points of intravenous StemBell administration in a rat model of acute myocardial infarction.

    abstract:BACKGROUND:Adipose-derived stromal cells (ASCs) are a promising new therapeutic option for patients with acute myocardial infarction (AMI). Previously, we found that ASCs coupled to antibody-targeted microbubbles (StemBells [StBs]) improved cardiac function when administered intravenously 7 days post-AMI in rats. In th...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2016.10.004

    authors: Emmens RW,Oedayrajsingh-Varma M,Woudstra L,Kamp O,Meinster E,van Dijk A,Helder MN,Wouters D,Zeerleder S,van Ham SM,de Jong N,Niessen HW,Juffermans LJ,Krijnen PA

    更新日期:2017-01-01 00:00:00

  • Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.

    abstract:BACKGROUND AIMS:Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has proven effective in metastatic melanoma and should therefore be explored in other types of cancer. The aim of this study was to examine the feasibility of potentially expanding clinically relevant quantities of tumor-specific T-cell cultures ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2011.563291

    authors: Junker N,Andersen MH,Wenandy L,Dombernowsky SL,Kiss K,Sørensen CH,Therkildsen MH,Von Buchwald C,Andersen E,Straten PT,Svane IM

    更新日期:2011-08-01 00:00:00

  • International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

    abstract::Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-phase clinical trials in both industry and academic sponsored studies. There is a broad consensus that despite different tissue sourci...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.11.008

    authors: Galipeau J,Krampera M,Barrett J,Dazzi F,Deans RJ,DeBruijn J,Dominici M,Fibbe WE,Gee AP,Gimble JM,Hematti P,Koh MB,LeBlanc K,Martin I,McNiece IK,Mendicino M,Oh S,Ortiz L,Phinney DG,Planat V,Shi Y,Stroncek DF,Vi

    更新日期:2016-02-01 00:00:00

  • CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.

    abstract:BACKGROUND:Traditionally, following high-dose therapy (HDT), unmanipulated autologous PBPC are infused. Alternatively, purified CD34+ cells can now be obtained by immunomagnetic separation using the CliniMACS device. Limited data currently exist examining hemopoietic recovery with such cells. METHODS:Ten patients with...

    journal_title:Cytotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1080/146532402317381857

    authors: Prince HM,Wall D,Rischin D,Toner GC,Seymour JF,Blakey D,Haylock D,Simmons P,Wolf M,Januszewicz EH,Westerman D,Richardson G,Scarlett J,Briggs P

    更新日期:2002-01-01 00:00:00

  • Intravenous infusion of adipose-derived stem/stromal cells improves functional recovery of rats with spinal cord injury.

    abstract:BACKGROUND AIMS:Adipose tissue has therapeutic potential for spinal cord injury (SCI) because it contains multipotent cells known as adipose-derived stem/stromal cells (ASCs). In this study, we attempted intravenous ASC transplantation in rats with SCI to examine the effect on functional recovery. METHODS:ASCs (2.5 × ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.04.002

    authors: Ohta Y,Hamaguchi A,Ootaki M,Watanabe M,Takeba Y,Iiri T,Matsumoto N,Takenaga M

    更新日期:2017-07-01 00:00:00

  • Effects of stem cells on non-ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials.

    abstract:BACKGROUND AIMS:To assess the impacts of stem cell therapy on clinical outcomes in patients with non-ischemic cardiomyopathy (NICM). The effect of stem cell therapy on prognosis is unclear and controversial. METHODS:The authors performed a systematic review and meta-analysis of the effects of autologous stem cell tran...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2020.06.006

    authors: Xia L,Zeng L,Pan J,Ding Y

    更新日期:2020-12-01 00:00:00

  • Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.

    abstract:BACKGROUND:There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinical scale method to prepare autologous DCs for cancer clinical trials. METHODS:PBMC were collected from normal donors or cancer patients by automated leukapheresis...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/146532401753156377

    authors: Wong EC,Maher VE,Hines K,Lee J,Carter CS,Goletz T,Kopp W,Mackall CL,Berzofsky J,Read EJ

    更新日期:2001-01-01 00:00:00

  • Safety and efficacy of granulocyte-colony-stimulating factor administration following autologous intramuscular implantation of bone marrow mononuclear cells: a randomized controlled trial in patients with advanced lower limb ischemia.

    abstract:BACKGROUND AIMS:The aim was to investigate the therapeutic effect of granulocyte-colony-stimulating factor (G-CSF) administration following implantation of autologous bone marrow mononuclear cells (BM MNC) for patients with lower limb ischemia. METHODS:The design was a randomized controlled trial. Fifteen patients wit...

    journal_title:Cytotherapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/14653240903518163

    authors: Zafarghandi MR,Ravari H,Aghdami N,Namiri M,Moazzami K,Taghiabadi E,Fazel A,Pournasr B,Farrokhi A,Sharifian RA,Salimi J,Moini M,Baharvand H

    更新日期:2010-10-01 00:00:00

  • A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

    abstract:BACKGROUND AIMS:Umbilical cord blood transplantation (UCBT) is increasingly used to treat acute leukemias. UCB units are thawed and infused in their entirety at transplant, precluding later use as immunotherapy to prevent or treat leukemia relapse. METHODS:We developed a device that selectively thaws only 1 mL of the ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.07.020

    authors: Vasu S,Berg M,Davidson-Moncada J,Tian X,Cullis H,Childs RW

    更新日期:2015-11-01 00:00:00

  • Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease.

    abstract:BACKGROUND AIMS:Allogeneic hematopoietic stem cell transplantation is curative for sickle cell disease, and the use of matched related donors, non-myeloablative conditioning and sirolimus immunosuppression results in stable mixed chimerism without graft-versus-host disease (GVHD). However, the time to terminate sirolim...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2019.10.003

    authors: Raines LN,Hsieh MM,Nassehi T,Drysdale CM,Tisdale JF,Uchida N

    更新日期:2019-12-01 00:00:00